Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system
Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in oncogenes. It is particularly suited for the analysis of rare mutations in precious samples such as circulating cell-free DNA (ccfDNA) from blood and other body fluids. For reliable detection of single base exchanges at low frequency, both, a reproducibly working dPCR system and optimized PCR assays, are indispensable. Locked Nucleic Acid (LNA)-enhanced oligonucleotides with substantially high levels of affinity for their complementary sequences make these assays excellent tools for the detection and discrimination of highly similar DNA targets.
About the speaker
Dr. Özlem Karalay, Senior Scientist, Digital PCR Assay Development
Özlem Karalay studied Molecular Biology & Genetics at the Middle East Technical University, Turkey, and obtained her M.Sc. degree in Neuroscience from the MPI for Developmental Biology, Tübingen. She received her doctorate in Neuroscience from the Swiss Federal Institute of Technology (ETH), Zürich. She joined QIAGEN after completion of her postdoctoral research at the MPI for Biology of Ageing, Köln, and since then has been involved in developing the digital PCR assay portfolio, including mutation detection and CNV assays.
Date of recording:Sunday, March 7, 2021
Academic Basic Research
Cancer (other / various)
Informatics & Data